Business
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results\n\n\n\n\n Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE)\n \n\n\n\n Cash runway to fund operations out to third quarter of 2026\n \n\n\n\n Company to host webinar to discuss updated data from the RESOLVE trial on May 9th\n \n\n\n VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quarter of 2025. All dollar values are in U.S. dollars unless stated otherwise.\n \n\n “We recently achieved a significant clinical milestone with the release of positive nine-month data from our ongoing open-label, dose-escalation Phase 1b/2a RESOLVE trial, which continue to support EP-104GI as a potentially transformative therapy for eosinophilic esophagitis,” said Dr. James Helliwell, Chief Executive Officer of Eupraxia. “The sustained or improved treatment outcomes observed over a nine-month period after a single treatment with 48mg dose of EP-104GI is a promising finding in the treatment of EoE with an injectable delivery system. We believe these results provide further evidence of the precision and durability of our DiffuSphere™ technology and provide a strong foundation as we advance into higher-dose cohorts in the coming quarters.”\n \n\n The Company will host a webinar with guest, Dr. Evan Dellon, to discuss data from the RESOLVE trial on Friday, May 9th at 9:00am ET (\n \n Link to register\n \n ).\n \n\n\n Recent Operational and Financial Highlights\n \n\n\n\n On February 18, 2025, the Company announced the return of seasoned capital markets executive Alex Rothwell to the role of Chief Financial Officer, succeeding the retiring Bruce Cousins.\n \n\n On February 25, 2025, the Company announced positive 12-week data from the sixth cohort of the ongoing RESOLVE trial in patients with eosinophilic esophagitis (“EoE”) noting no adverse events and continued positive data on effic...